Platform presentation in the late-breaking session of the annual International Symposium on ALS/MND: “Randomized, Phase II Trial of Arimoclomol in Rapidly Progressive SOD1 ALS”

The promising finding of this phase II trial has led to the 2018 launch of a phase III trial in the general ALS population.